RxDoctor Payments Data

Robert Castroll, MD

Psychiatry · Smithtown, NYNPI 1407929003

Payments from drug & device makers

$19,837in general payments, 2019–2025

Across 874 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Validus Pharmaceuticals LLC$2K
  • Alkermes, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • plus $10K from 30 others

What the payments were for

  • Food & beverage$19,774100%
  • Education$630%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,837 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$224,878
Medicare patients
255
Services billed
2,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$128,164
VraylarCariprazine Hcl26$55,622
TrintellixVortioxetine Hydrobromide12$14,591
QuviviqDaridorexant Hcl27$12,660
VyvanseLisdexamfetamine Dimesylate11$9,027
Clozapine129$8,483
Aripiprazole125$7,299
Lurasidone Hcl20$6,348
Dextroamphetamine Sulfate23$4,575
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl36$3,861
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine95$3,367
Bupropion XlBupropion Hcl145$3,303
Alprazolam410$3,071
Temazepam47$2,750
Quetiapine Fumarate98$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,733$128,16411 claims
AbbVieVraylar$2,061$55,62226 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$743$23,61823 claims
Idorsia Pharmaceuticals US IncQuviviq$248$12,66027 claims
Almatica Pharma LLCSertraline Hcl$238$1,047129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →